MX2019001771A - Composición farmacéutica sólida que comprende el sofosbuvir amorfo. - Google Patents

Composición farmacéutica sólida que comprende el sofosbuvir amorfo.

Info

Publication number
MX2019001771A
MX2019001771A MX2019001771A MX2019001771A MX2019001771A MX 2019001771 A MX2019001771 A MX 2019001771A MX 2019001771 A MX2019001771 A MX 2019001771A MX 2019001771 A MX2019001771 A MX 2019001771A MX 2019001771 A MX2019001771 A MX 2019001771A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
solid pharmaceutical
sofosbuvir
amorphous sofosbuvir
solid
Prior art date
Application number
MX2019001771A
Other languages
English (en)
Inventor
Seminara Stefano
Tajchert Agnieszka
Schwarz Franz
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of MX2019001771A publication Critical patent/MX2019001771A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Abstract

Se proporciona una composición farmacéutica sólida, la cual comprende el sofosbuvir, uno o más excipientes farmacéuticamente aceptables y, de una forma opcional, por lo menos un compuesto de matriz farmacéuticamente aceptable, en donde por lo menos el 99 por ciento en peso del sofosbuvir comprendido en la composición farmacéutica sólida está presente en una forma amorfa. La forma amorfa de sofosbuvir es estable en la composición farmacéutica sólica.
MX2019001771A 2016-08-12 2017-08-09 Composición farmacéutica sólida que comprende el sofosbuvir amorfo. MX2019001771A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16184053 2016-08-12
PCT/EP2017/070215 WO2018029262A1 (en) 2016-08-12 2017-08-09 Solid pharmaceutical composition comprising amorphous sofosbuvir

Publications (1)

Publication Number Publication Date
MX2019001771A true MX2019001771A (es) 2019-11-18

Family

ID=56684527

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001771A MX2019001771A (es) 2016-08-12 2017-08-09 Composición farmacéutica sólida que comprende el sofosbuvir amorfo.

Country Status (11)

Country Link
US (1) US20190167706A1 (es)
EP (1) EP3496705A1 (es)
JP (1) JP2019530645A (es)
KR (1) KR20190038881A (es)
CN (1) CN109862884A (es)
AU (1) AU2017309302A1 (es)
BR (1) BR112019002729A2 (es)
CA (1) CA3033319A1 (es)
MX (1) MX2019001771A (es)
RU (1) RU2019106294A (es)
WO (1) WO2018029262A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110214711A (zh) * 2019-06-28 2019-09-10 昱庆塑胶五金制品（惠州）有限公司 智能宠物喂食器
CN111467363A (zh) * 2020-04-07 2020-07-31 中国科学院深圳先进技术研究院 索非布韦在制备预防和治疗冠状病毒的药物中的应用
CN111773192A (zh) * 2020-08-18 2020-10-16 福建广生堂药业股份有限公司 一种索磷布韦片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
SG184323A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasett Llc Stereoselective synthesis of phosphorus containing actives
EP2907505A3 (en) 2011-12-29 2015-12-30 Abbvie Inc. Solid compositions comprising an HCV inhibitor
WO2015132321A1 (en) * 2014-03-05 2015-09-11 Galenicum Health S.L. Stable pharmaceutical compositions of sofosbuvir
CA2943574A1 (en) * 2014-04-03 2015-10-08 Sandoz Ag Solid composition comprising amorphous sofosbuvir
WO2016038542A2 (en) * 2014-09-10 2016-03-17 Mylan Laboratories Limited Polymorphic forms of sofosbuvir
CN104586802B (zh) * 2015-02-02 2018-01-16 长春海悦药业股份有限公司 一种含有索菲布韦的药物组合物

Also Published As

Publication number Publication date
CA3033319A1 (en) 2018-02-15
BR112019002729A2 (pt) 2019-05-14
WO2018029262A1 (en) 2018-02-15
JP2019530645A (ja) 2019-10-24
EP3496705A1 (en) 2019-06-19
CN109862884A (zh) 2019-06-07
AU2017309302A1 (en) 2019-02-21
US20190167706A1 (en) 2019-06-06
KR20190038881A (ko) 2019-04-09
RU2019106294A (ru) 2020-09-21

Similar Documents

Publication Publication Date Title
MX2019009842A (es) Composicion solida que comprende sofosbuvir amorfo.
WO2016131067A3 (en) Pharmaceutical compositions comprising meloxicam
MX2018007704A (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
EP4268892A3 (en) Matrix bound nanovesicles and their use
MY190855A (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
SG10201902203VA (en) Eutectic formulations of cyclobenzaprine hydrochloride
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
MX2019001771A (es) Composición farmacéutica sólida que comprende el sofosbuvir amorfo.
EP3760195A4 (en) COMPOSITION WITH 2,3-BUTANEDIOL AS THE ACTIVE SUBSTANCE
EP3539978A4 (en) NKX3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION WITH IT AS THE ACTIVE INGREDIENT
MY191219A (en) Therapeutic agent for fibrosis
MX2016017142A (es) Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
MX2021010022A (es) Composicion farmaceutica.
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
WO2015100370A3 (en) Sustained release depot formulations of therapeutic proteins, and uses thereof
TR201722603A2 (tr) Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari
EA201991265A1 (ru) Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат
GB201915828D0 (en) Compounds, compositions and therapeutic uses thereof
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
WO2017064652A3 (en) Low dose oral dipyridamole compositions and uses thereof
IL282999A (en) 4,3,1-oxadiazolone compound and drug
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
MX2019015869A (es) Nuevas formulaciones orales de belinostat.